119-s832

[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[S. 832 Introduced in Senate

    (IS) ]

<DOC>

119th CONGRESS
 1st Session
 S. 832

 To amend title XI of the Social Security Act to equalize the 
negotiation period between small-molecule and biologic candidates under 
 the Drug Price Negotiation Program.

_______________________________________________________________________

 IN THE SENATE OF THE UNITED STATES

 March 4, 2025

Mr. Tillis (for himself, Mr. Budd, Mrs. Blackburn, Mr. Daines, and Mr. 
 Lankford) introduced the following bill; which was read twice and 
 referred to the Committee on Finance

_______________________________________________________________________

 A BILL

 To amend title XI of the Social Security Act to equalize the 
negotiation period between small-molecule and biologic candidates under 
 the Drug Price Negotiation Program.

 Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

 This Act may be cited as the ``Ensuring Pathways to Innovative 
Cures Act of 2025'' or the ``EPIC Act of 2025''.

SEC. 2. EQUALIZING THE NEGOTIATION PERIOD BETWEEN SMALL-MOLECULE AND 
 BIOLOGIC CANDIDATES UNDER THE DRUG PRICE NEGOTIATION 
 PROGRAM.

 

Section 1192

    (e)

    (1)
        (A)
            (ii) of the Social Security Act (42 U.S.C. 
1320f-1

    (e)

    (1)
        (A)
            (ii) ) is amended--

    (1) by striking ``year, at least 7'' and inserting ``year--
 ``
            (I) for initial price 
 applicability years 2026 and 2027, at 
 least 7''; and

    (2) by adding at the end the following:
 ``
            (II) for initial price 
 applicability year 2028 and each 
 subsequent initial price applicability 
 year, at least 11 years will have 
 elapsed since the date of such 
 approval; and''.
 <all>